Back to top
more

Collegium Pharmaceutical (COLL)

(Delayed Data from NSDQ)

$34.15 USD

34.15
401,949

+1.68 (5.17%)

Updated May 20, 2024 04:00 PM ET

After-Market: $34.15 0.00 (0.00%) 6:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 249)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Collegium Pharmaceutical (COLL) Reports Q2 Loss, Tops Revenue Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 65.91% and 4.06%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Nektar (NKTR) Seeks Approval for Analgesic Opioid Candidate

    Nektar (NKTR) submits NDA to the FDA seeking approval of its analgesic opioid candidate, NKTR-181, for the treatment of chronic low back pain.

      What's in Store for Penumbra (PEN) This Earnings Season?

      Penumbra (PEN) deepens its focus on driving innovation, ramping up production and expanding geographies.

        Collegium Pharmaceutical, Inc. (COLL) Sees Hammer Chart Pattern: Time to Buy?

        Collegium Pharmaceutical, Inc. (COLL) Sees Hammer Chart Pattern: Time to Buy?

          Sage Therapeutics Soars: Stock Adds 7.1% in Session

          Sage Therapeutics (SAGE) was a big mover last session, as the company saw its shares rise more than 7% on the day.

            Valeant (VRX) in Focus: Stock Moves 11.7% Higher

            Valeant Pharmaceuticals International (VRX) was a big mover last session, as the company saw its shares rise nearly 12% on the day.

              Top Ranked Momentum Stocks to Buy for November 27th

              Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 27th:

                Top Ranked Momentum Stocks to Buy for November 22nd

                Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 22nd:

                  Collegium (COLL) in Focus: Stock Moves 6.9% Higher

                  Collegium Pharmaceutical (COLL) was a big mover last session, as the company saw its shares rise nearly 7% on the day amid huge volumes.

                    Top Ranked Momentum Stocks to Buy for November 16th

                    Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 16th:

                      Top Ranked Momentum Stocks to Buy for November 14th

                      Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 14th:

                        Collegium Pharmaceutical (COLL) Looks Good: Stock Adds 6% in Session

                        Collegium Pharmaceutical (COLL) shares rose 6% in the last trading session, amid huge volumes.

                          BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End

                          BioDelivery Sciences (BDSI) President and CEO, Mark Sirgo, is set to retire this year.

                            BioDelivery (BDSI) Q2 Loss Wider than Expected, Stock Falls

                            BioDelivery Sciences International (BDSI) reported wider-than-expected Q2 loss. However, Belbuca registered record sales for the second consecutive quarter.

                              Nektar's NKTR-181 Positive in Human Abuse Potential Study

                              Positive top line results from an oral human abuse potential (HAP) study, evaluating the opioid analgesic candidate -- NKTR-181 -- to assess abuse potential compared with oxycodone, nudged up Nektar's (NKTR) shares.

                                Nektar's Pain Drug Positive in Phase III Study; Shares Gain

                                Nektar Therapeutics??? (NKTR) shares surged 42.6% after the company announced positive results from a phase III efficacy study evaluating its investigational candidate, NKTR-181, in patients with moderate to severe chronic low back pain.